European Medicines Agency (EMA) grants Orphan Designation for AOC 1001 EP News Bureau Aug 25, 2021 The FDA cleared Avidity to proceed with the phase-I/II Marinatm trial of AOC 1001 in adults with myotonic dystrophy type 1 (DM1)…
Prestige Biopharma drug gets positive EMA opinion on Orphan Designation to treat pancreatic cancer EP News Bureau Oct 19, 2020 PBP1510 has already received ODD status from the US FDA in June 2020
